JP2023549494A5 - - Google Patents
Info
- Publication number
- JP2023549494A5 JP2023549494A5 JP2023528356A JP2023528356A JP2023549494A5 JP 2023549494 A5 JP2023549494 A5 JP 2023549494A5 JP 2023528356 A JP2023528356 A JP 2023528356A JP 2023528356 A JP2023528356 A JP 2023528356A JP 2023549494 A5 JP2023549494 A5 JP 2023549494A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- stereoisomer
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113557P | 2020-11-13 | 2020-11-13 | |
| US202063113555P | 2020-11-13 | 2020-11-13 | |
| US63/113,557 | 2020-11-13 | ||
| US63/113,555 | 2020-11-13 | ||
| US202163170855P | 2021-04-05 | 2021-04-05 | |
| US63/170,855 | 2021-04-05 | ||
| US202163225282P | 2021-07-23 | 2021-07-23 | |
| US63/225,282 | 2021-07-23 | ||
| PCT/US2021/058978 WO2022103960A1 (en) | 2020-11-13 | 2021-11-11 | Dichlorophenol hsd17b13 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549494A JP2023549494A (ja) | 2023-11-27 |
| JP2023549494A5 true JP2023549494A5 (enExample) | 2024-10-23 |
| JP7605984B2 JP7605984B2 (ja) | 2024-12-24 |
Family
ID=81602609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528356A Active JP7605984B2 (ja) | 2020-11-13 | 2021-11-11 | ジクロロフェノールｈｓｄ１７ｂ１３阻害剤およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11827619B2 (enExample) |
| EP (1) | EP4244210A4 (enExample) |
| JP (1) | JP7605984B2 (enExample) |
| KR (1) | KR102852264B1 (enExample) |
| CN (1) | CN116670118B (enExample) |
| AU (1) | AU2021377248B2 (enExample) |
| CA (1) | CA3198024A1 (enExample) |
| IL (1) | IL302764A (enExample) |
| MX (1) | MX2023005550A (enExample) |
| TW (1) | TWI893238B (enExample) |
| WO (1) | WO2022103960A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537271A (ja) | 2020-07-24 | 2023-08-31 | イニファーム，インク． | チオフェンｈｓｄ１７ｂ１３阻害剤とその使用 |
| CN116670118B (zh) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | 二氯苯酚hsd17b13抑制剂及其用途 |
| US12617772B2 (en) | 2021-04-05 | 2026-05-05 | Inipharm, Inc. | Hydroxypyridine HSD17B13 inhibitors and uses thereof |
| EP4469451A4 (en) * | 2022-01-26 | 2025-12-24 | Inipharm Inc | HSD17B13 2-SUBSTITUTE THIAZOLES INHIBITORS AND RELATED USES |
| HRP20251564T1 (hr) | 2022-05-19 | 2026-01-30 | Astrazeneca Ab | Amidni heteroaromatski spojevi korisni u liječenju bolesti jetre |
| WO2025024682A1 (en) * | 2023-07-26 | 2025-01-30 | Inipharm, Inc. | Methods of using dichlorophenol hsd17b13 inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2694711A (en) | 1952-12-02 | 1954-11-16 | American Cyanamid Co | Quinazolone antimalarial compounds |
| US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| DE19642451A1 (de) | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| JP4926473B2 (ja) | 2003-03-27 | 2012-05-09 | 協和発酵キリン株式会社 | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
| JP2008506761A (ja) | 2004-07-22 | 2008-03-06 | アステックス、セラピューティックス、リミテッド | プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体 |
| US20070010537A1 (en) | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| US20090163521A1 (en) | 2005-06-28 | 2009-06-25 | Orchid Research Laboratories Limited | Novel Pyrazolopyrimidinone Derivatives |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| EP1928865A1 (en) | 2005-08-17 | 2008-06-11 | Schering Corporation | Novel high affinity thiophene-based and furan-based kinase ligands |
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| US20120165330A1 (en) * | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
| CN103288771B (zh) | 2012-02-29 | 2014-12-03 | 中国中化股份有限公司 | 异噻唑类化合物及其作为杀菌剂的用途 |
| US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| CN105524053B (zh) | 2014-10-19 | 2020-06-05 | 广东东阳光药业有限公司 | 四氢苯并噻吩化合物 |
| WO2016081522A1 (en) | 2014-11-17 | 2016-05-26 | Rhode Island Hospital | Nanomaterial compositions, synthesis, and assembly |
| DK3356345T3 (da) | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| EP3404024B1 (en) | 2016-01-14 | 2020-11-18 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| KR101870968B1 (ko) | 2016-02-02 | 2018-06-25 | 부산대학교 산학협력단 | Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도 |
| MX376202B (es) | 2016-08-15 | 2025-03-07 | Lilly Co Eli | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. |
| TWI762634B (zh) | 2017-05-05 | 2022-05-01 | 大陸商上海赫普化醫藥技術有限公司 | 胺基-芳基-苯甲醯胺化合物及其使用方法 |
| EA202091897A1 (ru) | 2018-02-08 | 2020-10-27 | Энио Фарма | Неконденсированные производные тиофена и их применение |
| US20210000906A1 (en) | 2018-03-21 | 2021-01-07 | Ionis Pharmaceuticals, Inc. | Modulation of hsd17b13 expression |
| WO2020041741A1 (en) * | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| MA56457A (fr) | 2019-07-02 | 2022-05-11 | Regeneron Pharma | Modulateurs de hsd17b13 et leurs procédés d'utilisation |
| WO2021211974A1 (en) | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Hsd17b13 inhibitors and uses thereof |
| JP2023537271A (ja) | 2020-07-24 | 2023-08-31 | イニファーム，インク． | チオフェンｈｓｄ１７ｂ１３阻害剤とその使用 |
| CN116194440A (zh) | 2020-07-24 | 2023-05-30 | 伊尼制药公司 | 喹唑啉酮hsd17b13抑制剂及其用途 |
| IL299972A (en) | 2020-08-05 | 2023-03-01 | Enyo Pharma | Thiophane compounds for use in the treatment of renal fibrosis |
| WO2022040324A1 (en) | 2020-08-18 | 2022-02-24 | Metrea Biosciences, Inc. | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 |
| MX2023003677A (es) | 2020-09-30 | 2023-06-22 | Fl2022 001 Inc | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. |
| US20240083861A1 (en) | 2020-09-30 | 2024-03-14 | Fl2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| EP4221701A1 (en) | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| US20230416802A1 (en) | 2020-11-06 | 2023-12-28 | Inipharm, Inc. | Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatment |
| CN116670118B (zh) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | 二氯苯酚hsd17b13抑制剂及其用途 |
| EP4319872A4 (en) | 2021-04-05 | 2025-03-12 | Inipharm, Inc. | Thiazole/isothiazole hsd17b13 inhibitors and uses thereof |
| US12617772B2 (en) | 2021-04-05 | 2026-05-05 | Inipharm, Inc. | Hydroxypyridine HSD17B13 inhibitors and uses thereof |
| CA3229569A1 (en) | 2021-08-20 | 2023-02-23 | Enanta Pharmaceuticals, Inc. | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof |
| EP4469451A4 (en) | 2022-01-26 | 2025-12-24 | Inipharm Inc | HSD17B13 2-SUBSTITUTE THIAZOLES INHIBITORS AND RELATED USES |
| US20250340546A1 (en) | 2022-06-09 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hsd17b13 inhibitors |
-
2021
- 2021-11-11 CN CN202180090470.XA patent/CN116670118B/zh active Active
- 2021-11-11 TW TW110142108A patent/TWI893238B/zh active
- 2021-11-11 JP JP2023528356A patent/JP7605984B2/ja active Active
- 2021-11-11 WO PCT/US2021/058978 patent/WO2022103960A1/en not_active Ceased
- 2021-11-11 CA CA3198024A patent/CA3198024A1/en active Pending
- 2021-11-11 MX MX2023005550A patent/MX2023005550A/es unknown
- 2021-11-11 AU AU2021377248A patent/AU2021377248B2/en active Active
- 2021-11-11 IL IL302764A patent/IL302764A/en unknown
- 2021-11-11 KR KR1020237019074A patent/KR102852264B1/ko active Active
- 2021-11-11 EP EP21892809.1A patent/EP4244210A4/en active Pending
-
2023
- 2023-05-10 US US18/315,138 patent/US11827619B2/en active Active
- 2023-10-02 US US18/479,578 patent/US12227489B2/en active Active
-
2025
- 2025-01-08 US US19/013,234 patent/US20250376457A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520481A5 (enExample) | ||
| JP2024514223A5 (enExample) | ||
| JP2019104748A5 (enExample) | ||
| JP2024514837A5 (enExample) | ||
| JP2021183609A5 (enExample) | ||
| JP2023537271A5 (enExample) | ||
| JP2022505987A5 (enExample) | ||
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| JP2009504772A5 (enExample) | ||
| JP2023535453A5 (enExample) | ||
| JP2008510691A5 (enExample) | ||
| RU2020115095A (ru) | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 | |
| JP2009536221A5 (enExample) | ||
| JP2025503953A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2009505988A5 (enExample) | ||
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| JP2015531773A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
| JP2010520851A5 (enExample) | ||
| JP2020128426A5 (enExample) | ||
| JP2025507292A5 (enExample) | ||
| JP2025502943A5 (enExample) | ||
| EA201800118A1 (ru) | Фосфорамидатное нуклеозидное пролекарство для лечения вирусных и раковых заболеваний, способы его получения и использования |